Expression Profiles of Retinoblastoma Protein and p27Kip1 According to HER2 Amplification Status in Primary Breast Cancer

신재호,Sung-Jin Park,Hyun-Jin Cho,Geumhee Gwak,Byung-Noe Bae,Ki Whan Kim,Hong-Yong Kim2,Kyeongmee Park,Sehwan Han 한국유방암학회 2009 Journal of breast cancer Vol.12 No.1

Purpose: Human epidermal growth factor receptor-2 (HER-2)/neu amplification affects the cell proliferation through the modulation of multiple G1 cell cycle regulators in breast tumor cells. We performed this study to investigate whether retinoblastoma protein (pRB) and p27Kip1 were differently expressed according to the HER2 amplification status in human breast cancer. Methods: HER2 amplification was assayed by fluorescence in situ hybridization and the expression of cell cycle regulators were assayed by immunohistochemistry on 153 consecutive invasive breast cancers. The proliferative activity of breast cancer was analyzed according to the HER2 amplification and cell cycle protein expression status. Results: HER2 amplification was observed in 39 (25.5%) of 153 breast cancers. In the HER2 amplified breast cancers, the pRB expression was significantly increased (p=0.011) whereas there was no significant relationship between HER2 amplification and p27Kip1 expression. There was an inverse correlation between pRB expression and Ki-67 labeling index in the HER2 amplified breast cancers (p=0.036). In contrast, Ki67 labeling index was significantly decreased as p27Kip1 expression increased in HER2 non-amplified breast cancers (p=0.028). In HER2 non-amplified breast cancers, we could not observe any association between the pRB expression and Ki67 labeling index. Conclusion: The proliferation of the breast cancers was associated with pRB expression in HER2 amplified tumors whereas it was associated with p27Kip1 expression in HER2 non-amplified tumors. The results of the current study indicate that the cell proliferative activity of the breast cancer is under different growth signal pathways according to HER2 amplification status.

Focal adhesion kinase and src expression in premalignant and malignant skin lesions

( Ju Yeon Choi ),( Jae Yun Lim ),( Han Saem Kim ),( Jung Min ),( Jung In Kim ),( Hyun Min Seo ),( Sang Hyeon Hwang ),( Chong Won Choi ),( Yoon Hwan Kim ),( Jin Hee Sohn ),( Hyunjoo Lee ),( Won Serk Ki 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.2

Background: Focal adhesion kinase (FAK) and Src are non-receptor tyrosine kinases. FAK and Src play a critical role in inducing malignant transformation in tumor cells. Objectives: We performed immunohistochemical staining for total and phosphorylated forms of FAK and Src, to evaluate the role of FAK and Src in the development of premalignant and malignant skin lesions. Methods: A total of 59 facial skin samples (30 actinic keratoses, 10 Bowen``s diseases, 13 squamous cell carcinomas and six perilesional skins) were immunohistochemically stained for Ki-67, total (t) and phosphorylated (p) form of FAK and Src. Methods: A total of 59 facial skin samples (30 actinic keratoses, 10 Bowen``s diseases, 13 squamous cell carcinomas and six perilesional skins) were immunohistochemically stained for Ki-67, total (t) and phosphorylated (p) form of FAK and Src. Results: Cells positive for t-Src, p-Src-y530, t-FAK and pFAK-s722 were detected in premalignant intra-epithelial lesions (PELs) and squamous cell carcinomas (SCCs), but not in the perilesional skin. There was a tendency towards high correlation between Ki-67 and t-FAK or pFAK-s722, suggestive of the active role of FAK in cell proliferation. Conclusion: Our findings of higher t-Src and p-Src-y530 positive cells in PELs, as compared to SCCs (with higher Ki-67 level), are suggestive of the other role of Src in tumor formation and progression, which requires further investigation.

Tetrahydroisoquinoline Alkaloids가 쥐의 동맥과 뇌균등질의 α-Adrenoceptors에 미치는 영향

이현석,백선하,황수현,박인성,김은상,정진명,한종우,장기철,장기철 대한신경외과학회 1999 Journal of Korean neurosurgical society Vol.28 No.1

서울의 Penicillinase Producing Neisseria gonorrhoeae 발생빈도(1998)

김재홍,김준호,반재용,이정우,황성주,정준규,정성태,강진문,조흔정,홍창의,정혜신,이한승,김이선,이봉길,이종호,선영우,한기덕,윤성필,이성훈,안종성,박석범,문승현,조항래,김형섭,류지호,황재영,박준홍,손상욱 한양대학교 의과대학 2001 한양의대 학술지 Vol.21 No.1

In recent years, gonorrhea has been pandemic and remains one of the most common STDs in the world, especially in developing countries. For the detection of a more effective therapeutic regimen and assessing the prevalence of Penicillinase Producing Neisseria gonorrhoeae(PPNG), we have been trying to study the patients who have visited the Venereal Disease Clinic of Choong-Ku Public Health Center in Seoul since 1980 by menas of the chromogenic cephalosporin method. In 1998, 93 strians of N. genorrhoeae were isolated, among which 60(64.5%) were PPNG. The prevalence of PPNG in Seoul, which had been decreased to 39% in 1996 after a peak of 74.3% in 1993, is increased to 64.5% in 1998.

정신분열병에 대한 리스페리돈의 효과 및 안정성

이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1

연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.

Al_2O_3/MgAl_2O_4 복합체 제조시 혼합고정에 따른 미세구조 변화

한재호,피기태,박상엽 국립7개대학공동논문집간행위원회 2001 공업기술연구 Vol.1 No.-

In this study, the effect of mixing process on the microstructure of Al_2O_3/MgAl_2O_4 composites has been investigated. In using a MgO source for the formation of Mg-spinel, the addition of solution type Mg-nitrate showed more homogeneous microstructure compared to the case of addition of MgO powder. In a mixing process, the planetary-milling showed more homogeneous microstructure compared to conventional ball-milling process.

당뇨병환자에서 뇨증 Fibronectin농도의 증가에 관한 연구

한승범,조준승,손건영,서성문,박근용,조성래,박규영,박정모,이인규,여준기 啓明大學校 醫科大學 1994 계명의대학술지 Vol.13 No.4

Plasma fibronectin is an α₂-glyoprotein, which is produced by vascular endothelial cells. Raised level of plasma fibronectin has been observed in diabetic patients particularly in the presence of microvascular complications. However, no available data exist about urine level of this glycoprotein in diabetic patients. We measured urine fibronectin level by ELISA methods in 54 diabetic patients who have microvascular comlications or not. The following results were obtained. 1) Urine fibronectin level(㎍/g creatinine) in diabetic group(1740.0±678.0) is increased compaired with those in normal control group(471.0±59.0). but this results were not significantly different among two groups(P>0.05). 2) Urine fibronectin level(㎍/g creatinine) was significantly increased in patients with nephropathy (6188.0±3144.0) compared with those in normal control group(471.0±59.0) and patients without nephropathy(645.0±251.0)(P<0.001). 3) There were a significant correlation between BUN, creatinine, creatinine clearance, 24hr urine total protein and urine fibronectin level in diabetic patients. Our data suggest that urine fibronectin excretion level might be used as a sensitive guide for diabectic nephropathy.

심장질환에서 심장기능의 표지자로서의 혈청 가용성 CD4

한기주,김성구 순천향의학연구소 1998 Journal of Soonchunhyang Medical Science Vol.4 No.1

연구배경: 특발성 확장성심근증과 같은 심근질환의 병인의 하나로 면역기전이 작용하는 것이 최근 알려져 있으며 다른 원인의 심부전증의 병인과 진행에도 면역세포 및 cytokine들이 작용하는 것으로 알려졌다. 따라서 특발성 확장성심근증과 다른 원인의 심부전증 환자에게 세포 매개성 면역 반응이 활성화 되어 있다면 혈중에서 T 림프구의 활성도를 나타내는 혈청 가용성 CD4(sCD4)치가 상승될 것으로 기대된다. 대상및 방법: 심장병이 없는 대조군(10명)과 심부전이 있는 특발성 확장성심근증환자(5명)과 심장판막질환자(8명)에서 심도자 검사중 폐동맥 혈액에서 T 보조림프구의 면역작용 혈청표식자인 sCD4를 ELISA 방법을 이용하여 측정한 후 임상적 소견, 심초음파도 소견 및 심도자 소견과 비교 분석하였다. 결과: 1)혈청 sCD4 측정치는 대조군에서 1.75±2.05U/mL, 환장성 심근증환자에서는 7.59±3.29U/mL, 심장 판막질환자에서는 11.66±10.54U/mL로 심장질환군에서 유의하게 높았다(p<0.005, p<0.002). 2)심초음파도상 확장성심근증환자의 분획단축율과 심장판막질환자의 좌심실 이완기말내경은 혈청 sCD4치와 상관계수 각각 0.88(p<0.025), 0.90(p<0.001)의 유의한 상관관계가 있었다. 3)심도자 검사에서 측정한 확장성심근증 및 심장판막질환자의 평균 폐동맥압과 혈청 sCD4치와의 상관관계는 상관계수 0.45(p<0.05)의 유의한 상관관계가 있었다. 결론: 확장성심근증 및 심장 판막질환에서 T 림프구에 의한 면역반응이 진행되고 있음을 시사하며 혈청 sCD4치는 일부 혈역학적 소견과는 상관관계가 있었다. Background: There is growing evidence for pathogenic role of immune system activation in some myocardial disease. Recent report suggest that abnormalities of the cell-mediated immunity may involved in the pathogenesis of idiopathic dilated cardiomyopathy. Methods: Serum soluble-CD4(sCD4) as serologic marker of cell mediated immunity was measured by ELISA method in patients with valvular heart disease(n=6) and idiopathic dilated cardiomyopatly(n=5). We investigated the correlation between serum sCD4 levels and clinical, echocardiographic and cardiac catheterization parameters. Results; 1) Serum sCD4 level was 1.75±2.05U/mL in normal controls, 7.59±3.29U/mL in idiopathic cardiomyopathy, and 11.66±10.54U/mL in valvular heart failure. Concentration of serum sCD4 in the heart disease groups was significantly higher than that of normal control(p<0.005, p<0.002). 2)Serum sCD4 level had good correlation with fractional shortening in dilated cardiomyopathy(r=0.88, P<0.025) and left ventricular end diastolic dimension in valvular heart disease(r=0.90, p<0.025) and left significant correlation between mean pulmonary artery pressure and serum sCD4 level(r=0.45, p<0.05). Conclusions: Increased serum sCD4 levels suggest that an immune reaction is part of the pathogenesis of idiopathic dilated cardiomyopathy and valvular heart disease. Serum sCD4 levels have correlations with some hemodynamic parameters in patients with dilated cardiomyopathy and valvular heart disease.

육두구의 形態 鑑別에 관한 硏究

韓孝尙,吉基正,李暎鍾 대한본초학회 2005 大韓本草學會誌 Vol.20 No.1

Objectives : Myristicae Semen is the seed of Myristica fragrans Houttuyn. Recently, the seed of Myristica argentea Warburg is also sold as a fake of Myristicae Semen. Thus, in order to distinguish Myristica fragrans Houttuyn and Myristica argentea Warburg, their external, internal, and flour states were observed via microscopic examination. Method : The slice of the tested material made by paraffin section technique was colored with Safranine Malachite Green contrast methods, and the flour of it was mounted by the liquid made by the same ratio of each of glycerin, acetic acid, and water, and then observed and photographed by olymphus-BHT. Result 1. The seed of Myristica fragrans Houttuyn is oval with a length of 2~3cm and diameter of 1.5~2.5 cm, while the seed of Myristica argentea Warburg is of a longer oval shape with a length of 2.5?3.5cm and diameter of 1.5cm. 2. There was no difference between the internal parts of the cross-sections of Myristica fragrans Houttuyn and Myristica argentea Warburg. 3. There was no difference between the flour states of Myristica fragrans Houttuyn and Myristica argentea Warburg. Conclusion : There was a distinctive difference between the external forms of Myristica fragrans Houttuyn and Myristica argentea Warburg, while there was no significant difference in their internal and flour states. This makes it difficult to distinguish them via microscopic examination, when cut by cross-sections or grounded into flour states. Therefore, they should be distinguished through TLC, or some research on the characterising compound is needed.

Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer

Jung, So-Youn,Han, Wonshik,Lee, Jong Won,Ko, Eunyoung,Kim, Eunkyu,Yu, Jong-Han,Moon, Hyeong-Gon,Park, In Ae,Oh, Do-Youn,Im, Seock-Ah,Kim, Tae-You,Hwang, Ki-Tae,Kim, Sung-Won,Noh, Dong-Young Springer - Society of Surgical Oncology 2009 Annals of Surgical Oncology Vol.16 No.5